• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Genenta Science S.p.A.

    2/18/22 4:38:50 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email
    SC 13G 1 formsc13-g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS
    FILED PURSUANT TO RULE 13D-1(b), (c) AND (d)
    AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(b)

     

    Genenta Science S.p.A.
    (Name of Issuer)

     

    Ordinary Shares
    (Title of Class of Securities)

     

    36870W100
    (CUSIP Number)

     

    December 31, 2021
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1 (b)
      ☐ Rule 13d-1 (c)
      ☒ Rule 13d-1 (d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     

     
    CUSIP No. 36870W10013GPage 2 of 4 Pages

     

    1 NAME OF REPORTING PERSON  
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
      Luigi Naldini  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☒
         
    3 SEC USE ONLY  
         
         
    4 CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Italy  
    NUMBER OF 5 SOLE VOTING POWER  
    SHARES  
    BENEFICIALLY   1,386,145  
    OWNED BY 6 SHARED VOTING POWER  
    EACH      
    REPORTING   0  
    PERSON 7 SOLE DISPOSITIVE POWER  
           
        1,386,145  
      8 SHARED DISPOSITIVE POWER  
           
        0  
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      1,386,145  
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
         
         
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
         
      7.6%  
    12 TYPE OF REPORTING PERSON  
         
      IN  

     

    * Based on 18,216,858 ordinary shares outstanding as of December 31, 2021.

     

     
    CUSIP No. 36870W10013GPage 3 of 4 Pages

     

    Item 1(a). Name of Issuer: Genenta Science S.p.A.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices: Via Olgettina No. 58, 20132 Milan, Italy.
       
    Item 2(a). Name of Person Filing: Luigi Naldini.
       
    Item 2(b). Address of Principal Business Office or if none, Residence: Strada Malaspina 16, 20096 Milan, Italy.
       
    Item 2(c). Citizenship: Italy
       
    Item 2(d). Title of Class of Securities: Ordinary shares
       
    Item 2(e). CUSIP Number: 36870W100
       
    Item 3. Not Applicable
       
    Item 4. Ownership:
       

      (a)   Amount Beneficially Owned: 1,386,145.
           
      (b)   Percent of Class: 7.6%, based on 18,216,858 ordinary shares outstanding as of December 31, 2021.
           
      (c)   Number of shares as to which such person has:
           
          (i) sole power to vote or to direct the vote: 1,386,145
             
          (ii) shared power to vote or to direct the vote: 0
             
          (iii) sole power to dispose or to direct the disposition of: 1,386,145
             
          (iv) shared power to dispose or to direct the disposition of: 0
             

    Item 5. Ownership of Five Percent or Less of a Class: Not Applicable
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable
       
    Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: Not Applicable
       
    Item 8. Identification and Classification of Members of the Group: Not Applicable
       
    Item 9. Notice of Dissolution of Group: Not Applicable
       
    Item 10. Certification: Not Applicable

     

     
    CUSIP No. 36870W10013GPage 4 of 4 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 18, 2022
       
      /s/ Luigi Naldini
      Luigi Naldini

     

     

     

    Get the next $GNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

      ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

      6/29/23 9:11:48 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

      H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

      7/25/22 7:15:53 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

      MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global Biotech Tour" in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million

      4/15/25 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

      MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-pote

      3/19/25 9:28:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    SEC Filings

    See more
    • SEC Form 424B5 filed by Genenta Science S.p.A.

      424B5 - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:30:29 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Genenta Science S.p.A.

      20-F - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:25:59 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      3/19/25 9:27:03 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    Leadership Updates

    Live Leadership Updates

    See more
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/12/24 4:05:34 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/10/23 6:02:50 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genenta Science S.p.A.

      SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

      2/25/22 1:17:49 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care